Physician

Michael Paul Sherman, M.D., PHD

According to 2025 Medicare claims, Michael Sherman, M.D., PHD (NPI: 1164643359) practices hematology/oncology in the Oakland-Fremont-Berkeley, CA market, with the plurality of this provider's patient population coming from Contra Costa, CA. This provider's primary affiliated billing organization is MICHAEL P SHERMAN MD PHD, A MEDICAL CORPORATION (NPI: 1831201912; TIN: 202298787) and primary practice location at 94598-2415.

Sherman's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 800 traditional Medicare patients, billed 425,291 HCPCS/CPT codes, and received $8,120,740 in Medicare payments. The top billing code was 78815 (Nuclear medicine study from skull base to mid-thigh with ct scan). Part D data shows 1,637 prescription claims across 206 beneficiaries totaling $10,533,340 in drug costs, led by Xtandi (Enzalutamide). 2023 DME data shows 11 claims. Open Payments data shows 420 records totaling $8,865. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $1,465,085 to $10,533,340. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	696	555,496	$7,009,459
2016	725	542,065	$8,162,660
2017	749	535,432	$8,277,998
2018	747	531,113	$8,118,320
2019	777	429,050	$6,537,725
2020	763	472,628	$8,854,579
2021	771	423,655	$7,078,574
2022	780	484,481	$7,082,343
2023	773	419,715	$8,111,675
2024	800	425,291	$8,120,740

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	185	947	$1,465,085
2016	168	647	$899,186
2017	140	483	$452,891
2018	184	895	$2,714,761
2019	152	762	$2,938,903
2020	145	628	$3,324,219
2021	188	910	$5,311,336
2022	160	634	$2,687,639
2023	172	1,203	$7,811,395
2024	206	1,637	$10,533,340

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	11	$689
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	11	$527
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
78815	Nuclear medicine study from skull base to mid-thigh with ct scan	294	493	$1,744
A9552	Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries	220	404	$295
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	324	1,335	$173
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	457	1,457	$122
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	323	473	$78

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	103	3,090	$1,441,882
Brukinsa	Zanubrutinib	49	1,470	$722,011
Calquence	Acalabrutinib Maleate	51	1,530	$718,817
Erleada	Apalutamide	48	1,500	$689,311
Xgeva	Denosumab	179	5,012	$565,873

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	420	$8,865	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Michael Paul Sherman, M.D., PHD?

Tedicare shows public-source Medicare data for Michael Paul Sherman, M.D., PHD (NPI 1164643359), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Michael Paul Sherman, M.D., PHD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Michael Paul Sherman, M.D., PHD?

Michael Paul Sherman, M.D., PHD is linked to MICHAEL P SHERMAN MD PHD, A MEDICAL CORPORATION (billing NPI 1831201912) in the available physician profile data.

Does Michael Paul Sherman, M.D., PHD have Open Payments data?

Michael Paul Sherman, M.D., PHD has 420 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.